PHOX2A and Pruritus: Future studies could test whether established US Food and Drug Administration (FDA)–approved phosphodiesterase inhibitors (e.g., apremilast) or BMP pathway agonists can mimic the anti‐pruritic effects with Phox2a overexpression, thereby repurposing these agents or their derivatives as novel itch therapeutics.